Xipere launches in US
Click Here to Manage Email Alerts
Xipere, the first FDA-approved therapy for suprachoroidal use for the treatment of macular edema associated with uveitis, has been launched in the United States, according to a press release from Bausch + Lomb and Clearside Biomedical.
Xipere (triamcinolone acetonide injectable suspension) was approved in October 2021 based on the results of the phase 3 PEACHTREE trial. Among patients treated with Xipere, 47% achieved an improvement in best corrected visual acuity of at least 15 letters from baseline at 24 weeks compared with 16% of patients in the control arm (P < .01).
Suprachoroidal administration may facilitate more targeted delivery of therapeutic agents to the retina and choroid, according to the release.
“Throughout the past several months, we have been training eye care professionals all over the country on how to properly administer Xipere using its unique suprachoroidal injection method, which enables targeted delivery and compartmentalization of the medication,” Joseph C. Papa, chairman and CEO of Bausch Health, said in the release.
Read more about
Click Here to Manage Email Alerts